Neuraxis Plunges 11.88% After $5M Share Offering

On May 22, 2025, Neuraxis experienced a significant drop of 11.88% in pre-market trading, marking a notable decline in its stock performance.

Neuraxis recently announced a registered direct offering, raising $5 million through the issuance of new shares. This move is part of the company's strategy to bolster its financial position and support ongoing operations and future growth initiatives. The offering has been met with mixed reactions from investors, contributing to the recent volatility in the stock's price.

Despite the recent decline, Neuraxis remains focused on its core mission of advancing neurotechnology solutions. The company continues to invest in research and development, aiming to bring innovative products to market that address unmet medical needs and improve patient outcomes. The successful completion of the direct offering will provide Neuraxis with the necessary capital to pursue these goals and drive long-term value for shareholders.